Histiocytic sarcoma in dogs.

What it is

Histiocytic sarcoma (HS) is a malignant tumor of histiocyte-lineage cells (dendritic cells and macrophages). Three main clinical forms are recognized: a localized form (often in a limb joint or spleen), a disseminated form involving multiple organs, and the hemophagocytic form arising from splenic and bone marrow macrophages.

Bernese Mountain Dogs have a striking breed predisposition (much higher lifetime incidence than the general canine population). Flat-coated Retrievers, Rottweilers, and Golden Retrievers are also at elevated risk.

Signs to watch for

• Lameness with a peri-articular swelling (localized form near a joint, often the stifle or elbow).
• Unexplained weight loss, lethargy, or pale gums (disseminated or hemophagocytic forms).
• Coughing or labored breathing if lung involvement.
• Abdominal distention with splenic involvement.

How veterinarians diagnose it

FNA + cytology of an accessible mass is often the first step, but histopathology with immunohistochemistry (typically CD18 staining) is needed for confirmation — HS cells can resemble other round-cell tumors on cytology alone.

Staging is essential because the disseminated form behaves very differently from a single localized mass: chest radiographs or CT, abdominal ultrasound, bone marrow evaluation in some cases, and lymph node aspiration.

What treatment usually looks like

• Surgical excision for localized HS — sometimes amputation for limb tumors. The most curative path when feasible.
• Chemotherapy with lomustine (CCNU) is the most-evidenced systemic option, used adjuvantly after surgery for localized HS or as primary therapy for disseminated disease.
• Doxorubicin-based protocols are used in some cases, especially in combination.
• Splenectomy plus chemotherapy for the hemophagocytic form, though prognosis remains guarded.

Prognosis

Outcomes depend dramatically on subtype. Surgically resected localized HS treated with adjuvant lomustine has the best outcomes — some dogs achieve durable remission. Disseminated and hemophagocytic forms carry guarded-to-poor prognoses despite chemotherapy; published median survivals are typically in the months range.

Early diagnosis (catching the localized form before dissemination) is the single biggest factor in your favor. That's why a high index of suspicion in Bernese Mountain Dogs presenting with lameness is justified.

Questions to ask your vet

• Which subtype do we have — localized, disseminated, or hemophagocytic?
• Has the disease been fully staged?
• If localized, is surgery curative-intent? What about adjuvant lomustine?
• If disseminated, what's the realistic outcome and quality-of-life trajectory?
• Are there clinical trials for HS we should consider?

Where to learn more

Veterinary teaching hospitals at most accredited US vet schools maintain owner-facing fact sheets on common cancers. Peer-reviewed journals — JAVMA, Veterinary and Comparative Oncology, Frontiers in Veterinary Science — are accessible through PubMed. The American College of Veterinary Internal Medicine (ACVIM) and the Veterinary Cancer Society publish consensus statements you can ask your vet to walk you through.

For clinical trials enrolling dogs with this diagnosis, see the SciRouter Vet trial finder — we index AVMA, NCI COTC, and twelve university registries.